Maria Victoria C. Dizon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Victoria C. Dizon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Adam J. Friedman
Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
1 shared publication - David Chi Kong Luk
Department of Paediatrics and Adolescent Medicine, United Christian Hospital
1 shared publication - Eléa Thibault Greugny
Essential Health Translational Science, Johnson & Johnson Santé Beauté France Issy‐les‐Moulineaux France
1 shared publication - Georgios N. Stamatas
Johnson & Johnson Santé Beauté France, Paris, France
1 shared publication - Hequn Wang
Skin Health R&D, Johnson & Johnson Consumer Inc., Skillman, NJ, USA
1 shared publication - Jalil Bensaci
Essential Health Translational Science, Johnson & Johnson Santé Beauté France Issy‐les‐Moulineaux France
1 shared publication
Latest Publications
- Open Access
- 1 August 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (8) , 2049-2055.e1
A Predictive Self-Organizing Multicellular Computational Model of Infant Skin Permeability to Topically Applied Substances
- 1 August 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (8) , 2049-2055.e1
Open AccessA Predictive Self-Organizing Multicellular Computational Model of Infant Skin Permeability to Topically Applied Substances
- Open Access
- 12 December 2020
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (1) , 275-291
Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia
Introduction There is some evidence to suggest that the prevalence of atopic dermatitis (AD) in Asia is rising. We have therefore developed an algorithm for the topical treatment of AD throughout South and East Asia for use by primary care physicians, pediatricians and dermatologists. Methods Nine AD experts from South and East Asia and one from Europe developed the algorithm based upon treatment guidelines, relevant literature and local treatment practices. The algorithm outlines current best practice for the use of emollients, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), with the intention of simplifying the treatment regimen of mild-to-moderate AD in South and East Asia. Results Patients with AD should bathe and cleanse affected skin to remove crusts and scales daily. Emollients should also be applied daily as a maintenance treatment. When selecting appropriate topical anti-inflammatory treatment for AD flares, several factors should be taken into consideration, including the patient’s age, attitude to treatment options and site of AD lesions. Given the concerns regarding the risk of skin atrophy with use of TCS, a TCI should be used to treat AD lesions in sensitive skin areas: pimecrolimus is recommended for mild-to-moderate AD in these locations, while tacrolimus should be considered for moderate and severe cases. Either pimecrolimus or tacrolimus is recommended for flares in other, non-sensitive body locations. A proactive or intermittent maintenance treatment strategy involving regular emollient use and twice-weekly application of a TCI to previously affected areas is encouraged to reduce the risk of flares. Conclusions The algorithm proposed here is intended to simplify the topical treatment of mild-to-moderate AD in daily practice in South and East Asian countries.
- 12 December 2020
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (1) , 275-291
Open AccessPractical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia
Introduction There is some evidence to suggest that the prevalence of atopic dermatitis (AD) in Asia is rising. We have therefore developed an algorithm for the topical treatment of AD throughout South and East Asia for use by primary care physicians, pediatricians and dermatologists. Methods Nine AD experts from South and East Asia and one from Europe developed the algorithm based upon treatment guidelines, relevant literature and local treatment practices. The algorithm outlines current best practice for the use of emollients, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), with the intention of simplifying the treatment regimen of mild-to-moderate AD in South and East Asia. Results Patients with AD should bathe and cleanse affected skin to remove crusts and scales daily. Emollients should also be applied daily as a maintenance treatment. When selecting appropriate topical anti-inflammatory treatment for AD flares, several factors should be taken into consideration, including the patient’s age, attitude to treatment options and site of AD lesions. Given the concerns regarding the risk of skin atrophy with use of TCS, a TCI should be used to treat AD lesions in sensitive skin areas: pimecrolimus is recommended for mild-to-moderate AD in these locations, while tacrolimus should be considered for moderate and severe cases. Either pimecrolimus or tacrolimus is recommended for flares in other, non-sensitive body locations. A proactive or intermittent maintenance treatment strategy involving regular emollient use and twice-weekly application of a TCI to previously affected areas is encouraged to reduce the risk of flares. Conclusions The algorithm proposed here is intended to simplify the topical treatment of mild-to-moderate AD in daily practice in South and East Asian countries.